Halozyme Therapeutics, Inc. - HALO - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Halozyme Therapeutics, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
HALO	Nasdaq	8731	http://www.halozyme.com	7.57 -0.39
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Halozyme Therapeutics, Inc. Nasdaq stocks posting largest percentage increases - May 20th, 2013 4:05 pm 3 Humongous Health-Care Stocks This Week - May 18th, 2013 6:15 am HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh - May 17th, 2013 8:28 am Cancer Drug Drama Rocks 2 Biotech Stocks - May 16th, 2013 5:34 pm Halozyme rises on pancreatic cancer drug study - May 16th, 2013 2:41 pm Halozyme rises on pancreatic cancer drug study - May 16th, 2013 2:41 pm Halozyme rises on prostate cancer drug study - May 16th, 2013 2:15 pm Halozyme rises on prostate cancer drug study - May 16th, 2013 2:15 pm Little-noticed firm makes a splash with pancreatic cancer treatment - May 16th, 2013 12:25 pm [video] Biotech's Next Big Thing -- ASCO II - May 16th, 2013 12:09 pm Why Halozyme Therapeutics Shares Soared - May 16th, 2013 11:41 am Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting - May 15th, 2013 4:05 pm 10 ASCO '13 Abstracts You Can Read Right Now - May 15th, 2013 4:00 pm HALOZYME THERAPEUTICS INC Financials - May 15th, 2013 11:04 am Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) - May 15th, 2013 12:13 am Short Interest Increases 11.2% For HALO - May 10th, 2013 1:56 pm Halozyme Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript - May 8th, 2013 5:00 pm Halozyme Therapeutics Earnings: Here’s Why Investors are Ambivalent Now - May 8th, 2013 4:55 pm Halozyme Reports First Quarter 2013 Financial Results - May 8th, 2013 2:05 pm HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - May 8th, 2013 7:17 am View All Current Headlines >>